Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)

Gender-specific variation in sympathetic sensitivity (Fox et al., 2014; Fox and Sinha, 2009;
Cahill, 2003; Heinsbroek et al., 1991) may mean that guanfacine is particularly efficacious
in attenuating drinking in women, rather than men with Alcohol Use Disorder (AUD). Thus, the
investigators propose a double blind, placebo-controlled, 10-week randomized clinical trial
to examine the effects of Guanfacine XR (3mgs/daily) versus placebo in 60 women with AUD.
This will include twice weekly appointments comprising medical management and contingency
management protocols, collection of urine, breathalyzer screens, and vitals. Measures of
craving and mood will also be assessed. Parallel laboratory challenge studies will also be
conducted both on admission to out-patient treatment and again following 4 weeks of
treatment, in order to better elucidate the potentially therapeutic mechanisms of guanfacine.
Participants will be exposed to a personal stress versus relaxing imagery condition, 1
condition per day, in a randomized order. Craving, anxiety, mood, cognitive control, heart
rate and blood pressure (HRBP), and biological stress system markers will be assessed at
baseline, following imagery and at various recovery timepoints.

Inclusion Criteria:

- Must meet Diagnostic and Statistical Manual of Mental Disorders-V (DSM- V) criteria
for moderate to severe Alcohol Use Disorder (AUD),

- Must produce positive urine toxicology screens on admission to study

- Must demonstrate good health as verified by screening examination

- Must be able to read English and complete study evaluations

- Must be able to provide informed written and verbal consent

Exclusion Criteria:

- Meeting current use disorder for any other psychoactive substance, excluding nicotine.

- Having any other current Axis I psychiatric disorders or medical conditions requiring
treatment or medication

- EKG evidence at baseline screening of any clinically significant conduction
abnormalities including a Bazlett's QTc (corrected QT interval) of >470 msec.

- Must not be on monophasic contraceptives, nursing or pregnant.